Medical network - on March 28, from medicine, medical apparatus and instruments, to medical services, biotechnology, and precise medical treatment, medical robots. "Healthy China" strategic consideration a feast 10 trillion levels of the industry, various capital drool. 

 

In 2016, according to the number of China's medical industry mergers and acquisitions of more than 400, more than 180 billion, of which more than 20 billion overseas mergers and acquisitions, regardless of the number of mergers and acquisitions, record the amount or quality. "The spring of Chinese health service industry has only just begun." A well-known investor rhetoric: "the industry will appear more than $2017 in 1 billion merger scale." 

 

In 2017, how to occupy a place in the feast of the 10 trillion level? A few days ago, in the sixth China medical health industry investment and m&a CEO summit, dozens of Chinese and foreign industry higher-ups, began a round of brainstorming, industry mergers and acquisitions investment plan plan for 2017. 

 

The hospital is still the capital of a main direction 

 

As health industry to develop a "gold mine", become the capital for highland hospital, each capital is in the public hospital reform policy dividend. 

 

Medical industry investment in the industry point of view, in 2017, the "hole" will continue to stay in the field of medical services, including hospitals especially each capital. 

 

Statistics show that in 2016, the a-share listed company merger and acquisition assets for medical case as high as 235, involved in m&a mainly include Chinese and western medicine, health care supplies, equipment and technology, etc. Among them, medical services as "key battleground" become the capital for highland hospital. In 2016, a total of nine hospital assets of the listed company m&a. In 2017, the listed company "medical" passion surging, as of March 24, have been healthy for hk pharmaceutical, appropriate China six companies such as hospital merger and acquisition of assets. 

 

Health should be China, for example, in March, the subsidiary of transcribing Cyrus kang on $172.8 million acquisition of le co., LTD. 60% stake, benevolence and hospital become appropriate China health in the third hospital of jiangxi province layout. Since 2014 by the "medical" property transformation, tries to build up appropriate China health medical establishment as the core of the medical health industry platform, the current hospital logistic services, hospital management, it operates in cancer treatment and pension etc. Reporters YiHua group chairman of the board Liu Shaoxi understands, at present, the group has the "high-end health" as one of key layout of the fields in the future, will create a province of the largest and the most advanced international medical and rehabilitation pension based enterprises, service scope will be based on guangdong, radiation throughout the country, to overseas Chinese, covering southeast Asia. 

 

According to incomplete statistics, the current a-share listed company of civilian battalion hospital layout for nearly 40. Among them, the love, eye, topchoice group medical and constant kang medical mainly focus on the ophthalmology, dental, tumor and other specialized chain; Sig pharmaceutical, ma yinglong with advantages in the field of traditional Chinese medicine, such as active in hospital and outpatient construction of traditional Chinese medicine; Fosun medicine, China resources, Peking University, such as health care, health care, citic medical relying on years of accumulation, has become a domestic four medical group. 

 

Many listed companies executives said to the reporter, the positive "medical" because of China's public hospital reform policy dividends. In January of this year, the state council promulgated the "much starker choices-and graver consequences-in" health and health plan again, vigorously develop social do medical, relax services requirement of the medical institutions run by social forces, support social forces to take part in the health services in the form of a variety of. Otherwise, according to data in 2015, China's public hospital 14518, more than 13067 public hospitals. However, a public hospital revenue size is only about 10% of the public hospital, for more than 2000 2000 yuan only, far below the level of the western developed countries and Japan. Blue mountain capital founder and executive partner Liu Daozhi say: "the hospital development and investment management group has become China's a clear plan and long-term health development, and is also the main direction of social capital in the next few years." 

 

Hospital assets as health industry to develop a "gold mine", how to scientific and rational investment of merger and acquisition, extensive concern to the market. A broker medical health industry investment director told reporters: "ophthalmology, dental and orthopedic hospital operation is relatively stable and profit ability is stronger, is currently widely attract capital. Comprehensive hospital merger integration requires strong financial support in many aspects, mature management ability, otherwise the hospital may face operation and the risk of profit is difficult." In his view, the "medical" hot still need to cool thinking, enterprise mergers and acquisitions lead to hospital unsustainable blindly, finally still have to face a new round of industry merger and reorganization, and comprehensive strength of CRC medical, citic, Peking University medical and fosun medicine and so on four big medical group is expected to win. 

 

Notable is, from the current capital "medical" case, high-end hospital investment seems to favor generally. In terms of hospital location, hong CDH capital executive director Jiang Yanye pointed out from the Angle of investors, there are two kinds of hospital clinic for high-end route: one is gynecology and obstetrics, pediatrics and other areas of focus on service quality; 2 it is oral and medical beauty partial consumer market of small and beauty. 

 

However, three Po brain hospital, capital medical university, dean zhang is from hospital management practice concluded that the high-end technology is the core of the hospital the positioning of the key by technical ability. "Three Po management localization is technology, quality, service, technology first, quality is the price and high quality medical price, service is the respect for human nature in the process of medical services and care implanted in." Zhang, if private hospital medical technology ability not line, most people will vote with their feet, a lot of 3 armour hospital to public. Although are not satisfied with the service, the environment, but people eventually go is to solve the problem. 

 

Innovative drugs in the golden age 

 

Innovation in medicine are in the golden age. How to grasp the innovation medicine business opportunity? Is the consensus of many drug firms, while strengthen its research and development strength, still need to use the power of capital. 

 

If a hospital or health industry to develop a "gold mine", then the innovation medicine are usher in the golden age. Since 2015, the state about the strict new drug examination and approval, to carry out the reform measures such as generics consistency evaluation on the quality of drugs at the same time, the essence is to encourage drug companies active in new drug research and development, improve drug quality in our country. This year on March 17, state drug safety administration issued the decision of adjust the imported drug registration management related matters (draft) ", in the industry point of view, to innovation in our country medicine really is in line with international and Chinese drugs the synchronous global clinical listed brings positive effect. 

 

Wuxi's chief financial officer and chief investment officer zheng-guo hu said: "this is a very good aura." It is reported that the global annual output of new drugs is very low, is the best year in 2015, with 45 new drugs. In 2016, the FDA approved only 22 new drugs, the low over the past few years, new drug approvals is one year. Back to China, Europe and the United States listed on the new drug in the past decade, only a third on the market in China, the time delay of up to six to 10 years, to a certain extent hindered the development of innovative drugs in China and its clinical application. Zheng-guo hu said the countries accelerate for examination and approval of imported drugs, allowing the imported drugs in China and overseas synchronous declare clinical, is expected to shorten between China and Europe and the United States and other countries in the gap in development and application of innovative medicine. 

 

In the a-share market, innovative research and development strength strong beida pharmaceutical and hengrui pharmaceutical, letter litai, tasly pharmaceutical production enterprises, and ACTS as an important role in innovative drug research and development of pharmaceutical and outsourcing service companies such as tiger, bo teng co, bo dhi medicine, etc., will be in A series of innovative medicines policy dividend benefit fully. Beida pharmaceutical industry independent research and development of the national class 1 new drug, for ek, is China's first with independent intellectual property rights of small molecules targeting anticancer drugs, in the domestic treatment of lung cancer in 2015 small molecules targeting anticancer drugs market share has reached 28.16%, and there is still a large market space. It is reported that as of the end of June last year, beida pharmaceutical industry with a total of 20 research projects, involving six category and 2 kinds of new drugs in research projects. 

 

As domestic innovation medicine enterprise to develop pharmaceutical, founder and CEO of TongYou believed that Chinese medicine to achieve corner overtaking the key is to "focus on research and development of indigenous innovation." TongYou out at the same time part of a new drug companies failing: "macromolecular drugs, for example, many are in the case of others show targeted certainly can medicine, all rushed and do it." As a matter of fact, in terms of cancer, and countries such as Europe and the United States and China's cancer spectrum exists differentiation, in the incidence of gastric cancer, liver cancer and esophageal cancer in China is much higher than the west. "This is a warning to the Chinese new drug enterprises, we can't hope to foreign multinationals to help us solve the problem of serious diseases, we must depend on own strength to solve the carcinoma spectral differences, committed to the innovation of the local developed a better product." 

 

Medica capital partners lau leaf expressed approval: "in the domestic innovation environment to the good situation, increased investment in innovation medicine project in the future, new drug may account for over 50% of the fund. However, Matthew effect is very strong, new drug for the same target with the generation of drug, if in three to five away, we then it has no interest in." In their view, the current domestic drug firms most is still in the extensive new drug research and development. Investment in new drugs, focusing on drug into medicinal is safe and effective at the same time, also look at its commercial value - whether have clinical requirements? Can eventually have to sell? Did not meet the clinical demand is the biggest opportunity. 

 

How to grasp the innovation medicine business opportunity? Is the consensus of many drug firms, while strengthen its research and development strength, still need to use the power of capital. TongYou's advice: "according to the domestic clinical needs, in the field of research and development and new drug domestic enterprises is weak, can use the power of capital directly purchase foreign project, some of the more early clinical trials of these projects are carried out." Xinli's general manager assistant boss han also said that the new drugs and generic drugs distribution of resources, company is now more and more tend to put innovation medicine, the company will actively screening new technology, good projects in China and abroad to support letter litai and stronger innovation medicine plate. 

 

"The new health care" to release the new business opportunities 

 

The robot of artificial intelligence and medical applications as the main content of technology research, product development, and mergers and acquisitions investment could usher in a booming development, which are characterized by technology innovation and mode innovation of "new medicine" is gradually release the huge business opportunities. 

 

Writing for the first time this year the government work report "artificial intelligence", for the medicine sent a stock investment desire. In the sixth China medical health industry investment and m&a CEO summit, there are a number of entrepreneurs and investors believe that the robot of artificial intelligence and medical applications as the main content of technology research, product development, and mergers and acquisitions investment in booming, which are characterized by technology innovation and mode innovation of "new medicine" is gradually release enormous business opportunities. 

 

Data show that medical applications of artificial intelligence in the next five years will usher in explosive growth, applications will be involved in medical imaging, auxiliary diagnosis, drug development and health management, etc. In addition, medical robot industry will develop in the future five years of medical robots for 15 to 20 special medical system, satisfy some complexity surgery, including cardiovascular intervention, neurosurgery, vascular surgery, endoscopic surgery, the tumor surgery, etc. Blue mountain capital Liu Daozhi said, as the next few years operation of all kinds of apparatus of robot, the global medical robot industry scale will increase from $2015 in 7.47 billion to $2020 in 11.4 billion, is worth focusing on industry capital. 

 

Founding partner volcano capital ZhangSuYang like artificial intelligence "new medicine" released by the business opportunities. In its view, 2016 medical investment remains an unprecedented hot medical plate return on investment is also very considerable. In 2017, the medical investment fields may appear more new technology, such as the combination of artificial intelligence and medical. "The medical treatment in any development or technology convergence speed is very fast, the traditional industry, higher safety cushion emerging industries are fast becoming the potential of the unicorn. The medical industry in China in 2017 will appear more than $1 billion merger scale." 

 

Back in 2016 medical m&a cases, fosun medicine, bo real medical robots have the first layout market shares. Last December, fosun pharma intuitive medical instrument company to start the strategic cooperation with the United States, the two sides will jointly invest $100 million in a joint venture in Shanghai, the main research and development, production and sales for early lung cancer diagnosis and treatment of innovative products based on the technology of robot assisted catheter. Bo real stake in the suzhou high-tech zone administrative committee cooperation, boost in suzhou high-tech zone development of medical robot and intelligent equipment innovation industry. In addition, the chutian science and technology through constant increased to raise investment "annual output of 300 sets of high-end biomedical intelligent equipment and construction of medical robots", raising the level of intelligent in pharmaceutical production. 

 

Notable is, mainly in vitro diagnosis, genetic testing of biotechnology is becoming a capital in favor of "new medicine" darling. Reporter statistics found that 2016 a-share listed company merger and acquisition of biotechnology with 56 cases, accounts for about 24% of the total medical industry mergers and acquisitions, more than 10% from 2015. The current a-share market besides are IPO queuing genomics of da an gene, dean diagnosis, progress, existing organisms such as dozens of listed companies build on the "early" gene sequencing, grab to eat billions of level of precision medical market. 

 

Medicine investors generally believe that, with the advent of the era of precision medical treatment, biological technology, biological big data is not to be missed investment direction, including gene sequencing, editing and cellular immunotherapy has gradually become a hot market chase. The personage inside course of study points out, gene sequencing in reproductive health, cancer diagnosis and treatment, new drug research and development and application of medical basic research is more, noninvasive prenatal (NIPT) is one of the areas of high industrialization degree, the huge market space in the field of tumor. Liu Daozhi said: "the cellular immune treatment of this new type of treatment based on the genetic engineering technology, is becoming a new pillar for the treatment of cancer, is engaged in product development and promotion of the company created the extremely high market potential, also attract a lot of investment. In the past year or two, no matter the United States or China, investment in this area is very large." 

 

Divided by technological innovation driven by "new medicine" opportunities, business model innovation inspired by the "new medicine" opportunity also in nearly two years to get the double support of policy and capital, Internet medical is the representative. Than the mobile medical treatment, medical Internet in 2014 and 2014, the popular trend, in 2016 the industry investment and financing has become more rational. Share investment managing partner of yellow instead argues that Internet medical investment opportunities still exist, but need to reflect on, in the past two years, the market focused on C the opportunity, but the future service or more cash value for B. 

 

Liu Daozhi bluntly say, health is, in fact, a kind of Internet sharing economy in the medical application. In their view, the share of China's medical market potential is very huge, predicts 2020, the share of China's medical market scale will reach 80 billion, the main development of offline and online is the trend of the development of fusion, and emerging technologies and medical sharing interactive fusion depth.